The Third Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650000, China
Location contact
Lianhua Ye
CONTACT
Yantao Yang
PRINCIPAL_INVESTIGATOR
Yaowu Duan
CONTACT
NCT Number: NCT06645743
The purpose of this study is to provide a basis for the selection of surgical methods for patients with stage IA lung adenocarcinoma. Air cavity dissemination is a poor prognostic factor for patients with stage IA lung adenocarcinoma. We retrospectively collected clinical and imaging data of stage IA lung adenocarcinoma patients. Independent risk factors associated with spread through air space in stage IA lung adenocarcinoma patients were analyzed, so as to predict the occurrence of spread through air space and provide basis for the selection of surgical methods
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Kunming, Yunnan, 650000, China
Lianhua Ye
CONTACT
Yantao Yang
PRINCIPAL_INVESTIGATOR
Yaowu Duan
CONTACT
Referring from Global Cancer Report 2020, lung cancer remains the leading cause of tumor death, with adenocarcinoma as the primary histological subtype. In 2021, the World Health Organization (WHO) proposed a new classification standard for lung cancer, dividing adenocarcinomas into in-situ adenocarcinomas, microinvasive adenocarcinomas, and invasive adenocarcinomas based on their invasive development.
Due to the widespread popularization of early screening for lung cancer, a growing number of IA lung adenocarcinomas cases manifesting as lung nodules have been detected, and surgical resection remains the most critical treatment options for such individuals. With the emergence of relevant research results, sublobectomy has become a preferred method for early stage IA lung adenocarcinoma. However, some individuals with lung adenocarcinoma in stage IA undergoing sublobectomy still have recurrence and metastasis, in which spread through air spaces (STAS) plays vital role.
STAS was formally proposed by WHO in 2015 as a new invasion mode of invasive lung adenocarcinoma. STAS is characterized by pathological micropapillary clusters, solid nests, or isolated cells located beyond the tumor margin, counting one or more, infiltrating the air spaces within the surrounding lung parenchyma and detached from the primary tumor, rather than forming distinct tumor islands. A number of studies have pointed out that STAS is associated with poor prognosis of patients, many researchers continue to favor lobectomy when treating patients with stage IA lung adenocarcinoma exhibiting positive STAS.
Due to the limitations of intraoperative frozen section in predicting STAS, preoperative application of clinical and imaging features in predicting STAS shows great advantages. Former research has suggested that clinical and imaging characteristics can predict occurrence of STAS, despite the difference of results from different studies. Onozato et al. believe that smokers are more likely to develop STAS, which is consistent with the study by Shiono et al. However, Uruga et albelieved that the occurrence of STAS was unrelated to smoking. Warth et al. believed that male lung adenocarcinoma patients were more prone to STAS, while Kadota stated the occurrence of STAS was unrelated to patient gender.
However, the sample size included in these previous studies is small, and the parameters included by various scholars are different, and there is still a lack of large sample studies systematically analyzing clinical and imaging characteristics to predict the spread through air space of stage IA lung adenocarcinoma. Therefore, we plan to carry out this study. Based on a large sample size, the clinical and imaging characteristics of patients with stage IA lung adenocarcinoma were comprehensively analyzed to predict the spread through air space, so as to provide a reference for the selection of surgical methods
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Preoperative CT images reported that the maximum diameter of pulmonary nodules was less than 3 cm
All subjects provided CT imaging obtained from Yunnan Cancer Hospital within a 2-week period prior to surgery
Postoperative pathological diagnosis of invasive lung adenocarcinoma
Remote metastasis was excluded by preoperative imaging (CT, PET-CT, ultrasound, etc.)
Age ≥ 18 years
Exclusion criteria
Incomplete collection of medical records, imaging data, or hematology data
Preoperative complications of other malignant tumors
Unclear correspondence between postoperative pathological report and preoperative CT nodule location
Images do not meet analysis conditions due to pulmonary infection or large respiratory motion artifacts
Postoperative pathology revealed two or more nodules classified as infiltrating adenocarcinoma
Prior lung surgery or preoperative neoadjuvant therapy
Time frame: Preoperative clinical and imaging data collected within 2 weeks prior to surgery, retrospectively analyzed from patients who underwent surgery within the past 3 years
This outcome measure assesses the accuracy of using preoperative clinical and CT imaging features to predict the presence of spread through air spaces (STAS) in patients with stage IA lung adenocarcinoma.Measure: Area Under the ROC Curve (AUC), sensitivity, and specificity for the prediction model.
Time frame: From the date of surgery to the time of disease recurrence or last follow-up, up to 5 years.
This outcome measure investigates whether the presence of STAS in stage IA lung adenocarcinoma is associated with recurrence-free survival (RFS).
Contact information is provided by the study sponsor or research team.
Huilian Hu
CONTACT
Yantao Yang
CONTACT
The Third Affiliated Hospital of Kunming Medical College.
Other
Clinical and Imaging Features Were Used to Predict the Occurrence of Spread Through Air Space in Stage IA Lung Adenocarcinoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05675774
Brain Diseases, Cardiovascular Diseases
Winnipeg, Manitoba, Canada
View Trial DetailsNCT07016477
Aortic Valve Disease, Aortic Valve Stenosis
Charleston, South Carolina, United States
View Trial DetailsNCT07482605
Adenocarcinoma, Adenocarcinoma of Lung
View Trial DetailsNCT07675876
Adenocarcinoma, Adenocarcinoma of Lung
Denver, Colorado, United States
View Trial Details